Literature DB >> 2743709

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.

M L Dahl-Puustinen1, A Lidén, C Alm, C Nordin, L Bertilsson.   

Abstract

The pharmacokinetics of a single oral dose of 6 mg perphenazine was studied in a group of six slow and six rapid hydroxylators of debrisoquin. Peak serum concentrations of perphenazine were significantly higher in slow hydroxylators than they were in rapid hydroxylators (2.4 +/- 0.6 versus 0.7 +/- 0.3 nmol/L, p less than 0.001). The AUC(0-12) was also higher in slow hydroxylators than it was in rapid hydroxylators (18.5 +/- 6.2 versus 4.5 +/- 2.5 nmol.L-1.hr, p less than 0.001). The data suggest that the disposition of the antipsychotic drug perphenazine covaries with polymorphic debrisoquin hydroxylation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743709     DOI: 10.1038/clpt.1989.109

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  37 in total

1.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.

Authors:  O V Olesen; K Linnet
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 3.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Inhibitors of imipramine metabolism by human liver microsomes.

Authors:  E Skjelbo; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

5.  Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.

Authors:  E Spina; M Ancione; A E Di Rosa; M Meduri; A P Caputi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 7.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

8.  Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers.

Authors:  G Movin-Osswald; A L Nordström; M Hammarlund-Udenaes; A Wahlén; L Farde
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.

Authors:  Jacek Wójcikowski; Lydiane Pichard-Garcia; Patrick Maurel; Władysława A Daniel
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.